trending Market Intelligence /marketintelligence/en/news-insights/trending/G1X039hUnL0DW27IpLZ9RA2 content esgSubNav
In This List

Forty Seven's blood cancer therapy gets US FDA fast-track status

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Forty Seven's blood cancer therapy gets US FDA fast-track status

Forty Seven Inc. said the U.S. Food and Drug Administration granted fast-track designation to its investigational blood cancer therapy magrolimab.

SNL Image

The Menlo Park, Calif.-based company is developing magrolimab as a potential treatment for myelodysplastic syndrome and acute myeloid leukemia. The former is a group of disorders that occur when the blood-forming cells in the bone marrow do not work properly; the latter is a cancer of the blood and bone marrow in which the bone marrow produces too many abnormal white blood cells known as myeloblasts.

The experimental drug, a monoclonal antibody against CD47, works by blocking the "don't eat me" signal used by cancer cells to avoid being absorbed by a type of white blood cells called macrophages.